期刊文献+

改良VTD方案治疗老年多发性骨髓瘤的效果及安全性分析 被引量:7

原文传递
导出
摘要 目的探讨改良VTD(硼替佐米联合沙利度胺+地塞米松)方案治疗老年多发性骨髓瘤(MM)的效果及不良反应。方法回顾性分析我院住院诊治的11例老年MM患者采用改良VTD方案治疗的效果及毒性反应。结果1例初治患者用药1个疗程后因经济原因停用,并失访。在可评估的10例(7例初治,3例难治或复发)患者中,中位随访14个月,完全缓解2例,接近完全缓解1例,部分缓解5例,微小反应(MR)1例,疾病进展1例。中位疾病无进展时间为11.5个月,初治及复发患者的疾病无进展时间分别为12.2个月和8.3个月。血液学不良反应以血小板减少、白细胞减少居多,非血液学毒性以乏力、胃肠道反应居多,周围神经病变2例,未观察到3、4级的周围神经病变发生。结论改良的VTD方案具有疗效高、安全性好、不良反应轻微等特点,尤其适合老年MM患者,可推广临床使用。
出处 《中国综合临床》 2012年第12期1252-1254,共3页 Clinical Medicine of China
  • 相关文献

参考文献14

  • 1Blade J,Samson D, Reeee D, el al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietie stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant [ J]. Br J Haematol, 1998, 102(5) :1115-1123. 被引量:1
  • 2Liu YJ, Zhu GP, Guan XY. Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma [ J ]. Oral 0ncol,2012,48(6) :554-559. 被引量:1
  • 3李菁媛,谢红,冉启杰,周敏,王军,张新华.小剂量硼替佐米联合地塞米松治疗复发难治性多发性骨髓瘤的疗效[J].临床内科杂志,2011,28(3):201-202. 被引量:4
  • 4Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma:final time-to-event results of the APEX trial [ J ]. Blood,2007,110 (10) :3557-3560. 被引量:1
  • 5Pineda-Roman M, Zangari M, van Rhee F, et al. VTD combination therapy with is highly effective in advanced and refractory multiple myeloma [J]. Leukemia,2008,22(7) : 1419-1427. 被引量:1
  • 6San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma [J]. N Engl J Med,2008,359(9) :906-917. 被引量:1
  • 7Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy [J]. J Clin Oncol,2009,27(21 ) :3518-3525. 被引量:1
  • 8Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [ J ]. N Engl J Med, 1999,341 (21) :1565-1571. 被引量:1
  • 9Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trims of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma [ J ]. Br J Haematol,2006,132 (5) : 584-593. 被引量:1
  • 10黄琰,韩效林,王红艳,李素霞,贺立山.小剂量沙利度胺联合地塞米松治疗多发性骨髓瘤的临床研究[J].中国煤炭工业医学杂志,2010,13(12):1831-1832. 被引量:4

二级参考文献19

  • 1华晓莹,曹祥山,谢晓宝,顾伟英,贺白.小剂量沙利度胺治疗多发性骨髓瘤的临床观察[J].白血病.淋巴瘤,2006,15(5):373-374. 被引量:10
  • 2刘桐宇,叶建新.蛋白酶体抑制剂治疗多药耐药肿瘤机制的研究进展[J].中华肿瘤防治杂志,2007,14(15):1187-1190. 被引量:6
  • 3Kane R C, Bross P F, Farrell A T, et al. Veleade: U. S. FDA approval for the treatment of multiple myeloma progressing on prior therapy[J]. Oncologist, 2003,8(6) :508-513. 被引量:1
  • 4Ogawa Y, Tobinai K, Ogura M, et al. Phase I and II pharmaco kinetic and pharmaeodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma[J]. Cancer Sci, 2008, 99(1) :140-144. 被引量:1
  • 5San Miguel J F, Richardson P G, Sonneveld P, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study[J]. Leukemia, 2008,22(4) :842-849. 被引量:1
  • 6Blade J, Samson D,Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation[J]. Br J Haematol, 1998,102(5):1115-1123. 被引量:1
  • 7Markovina S, Callander N S, O'Connor S L, et al. Bortezomibresistant nuclear factor-kappaB activity in multiple myeloma cells[J]. Mol Cancer Res, 2008,6(8) :1356-1364. 被引量:1
  • 8Boissy P,Andersen T L,Lund T,et al. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions [J].Leuk Res, 2008, 32(11) : 1661-1668. 被引量:1
  • 9yon Metzler I, Krebbel H, Hecht M, et al. Bortezomib inhibits human osteoclastogenesis [J]. Leukemia, 2007, 21 ( 9 ) : 2025- 2034. 被引量:1
  • 10Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma[J]. N Engl J Med,1999,341(21) :1565. 被引量:1

共引文献15

同被引文献68

  • 1武永吉.多发性骨髓瘤[M]//张之南,沈悌.血液病诊断及疗效标准.3版.北京:科学出版社,2007:232-235. 被引量:14
  • 2吴晓雄,于力,黄文荣,赵瑜,王全顺,薄剑,李菲,高春记.硼替佐米治疗难治/复发性多发性骨髓瘤的疗效观察[J].临床血液学杂志,2007,20(5):268-269. 被引量:14
  • 3Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma. Lancet, 2009,374:324-339. 被引量:1
  • 4Kyle RA, Gertz MA, Witzig TE,et al. Review of 1027 patients with newly diagnosed multiple mveloma. Mayo Clin Proc,2003,78:21-33. 被引量:1
  • 5Moumas E,Hanf W, Desport E, et al. New insights in the treatment of myeloma with renal failure. Nephrol Ther,2011,7 :457-466. 被引量:1
  • 6Roussou M, Kastritis E, Christoulas D, et al. Reversibility of renal fail- ure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res ,2010,34 : 1395-1397. 被引量:1
  • 7Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with muhiple myeloma treated by high-dose therapy and haemopoietie stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant [ J ]. Br J Haematol, 1998,102 ( 5 ) : 1115- 1123. 被引量:1
  • 8Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high - dose dexamethasone for relapsed multiple myeloma [ J 1. N Engl J Med,2005,352(24) :2487-2498. 被引量:1
  • 9LeeS J, Richardson PG, Sonneveld P, et al. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma:resuhs from the APEX study [ J]. Br J Haematol, 2008,143 (4) : 511- 519. 被引量:1
  • 10van de Velde H J, Liu X, Chen G, et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma [ J]. Haematologica,2007, 92(10) :1399-1406. 被引量:1

引证文献7

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部